STX-107
- Generic Name
- STX-107
- Drug Type
- Small Molecule
- Chemical Formula
- C18H10FN3S
- CAS Number
- 935685-90-8
- Unique Ingredient Identifier
- O55CA1TU5D
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
Phase 1
Completed
- Conditions
- mGluR5 Receptors
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 19
- Registration Number
- NCT01896843
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01325740
- Locations
- 🇺🇸
University of California-Davis, M.I.N.D. Institute, Sacramento, California, United States
🇺🇸University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States
🇺🇸University of California-Los Angeles Neuropsychiatric Institute, Los Angeles, California, United States
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Seaside Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00965432
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath